Sarepta Therapeutics
SRPT
366 hedge funds and large institutions have $7.21B invested in Sarepta Therapeutics in 2020 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 124 increasing their positions, 129 reducing their positions, and 71 closing their positions.
4% less repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 129
4.07% less ownership
Funds ownership: 98.84% → 94.77% (-4.1%)
6% less funds holding
Funds holding: 390 → 366 (-24)
18% less call options, than puts
Call options by funds: $172M | Put options by funds: $209M
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
24% less capital invested
Capital invested by funds: $9.51B → $7.21B (-$2.29B)
27% less first-time investments, than exits
New positions opened: 52 | Existing positions closed: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$168M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$107M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$53.4M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$40.4M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$40M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$187M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$87.2M |
| 3 |
CCM
Cadian Capital Management
New York
|
-$71M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.5M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$32.4M |
SRPT Hedge Fund Activity: Q1 2020 in Review
366 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q1 2020, worth a combined $7.21B — down 24% from $9.51B a quarter earlier.
Sellers outnumbered buyers: 71 funds closed out of SRPT and 52 opened new positions — a net loss of 19 holders — while 129 trimmed existing stakes and 124 added.
The largest buyer was Capital Research Global Investors, adding an estimated $168M. The largest seller was T. Rowe Price Associates, cutting an estimated $187M.
- 366 institutional investors held Sarepta Therapeutics (SRPT) as of Q1 2020, down from 390 in Q4 2019.
- Funds reported $7.21B of Sarepta Therapeutics stock for Q1 2020, down 24% quarter-over-quarter.
- 52 funds opened new Sarepta Therapeutics positions in Q1 2020 and 71 closed out, a net change of -19 holders.
- The largest Sarepta Therapeutics buyer in Q1 2020 was Capital Research Global Investors, an estimated $168M added.
- The largest Sarepta Therapeutics seller in Q1 2020 was T. Rowe Price Associates, an estimated $187M sold.
Based on aggregated 13F filings for Q1 2020.